questionsmedicales.fr
Maladies de l'appareil respiratoire
Maladies pulmonaires
Poumon hyperclair
Poumon hyperclair : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Radiographie
Scanner
Poumon hyperclair
Tomodensitométrie
Tests fonctionnels respiratoires
Densité pulmonaire
Radiologie
Hyperinflation
Physiologique
Anamnèse
Maladies respiratoires
Symptômes
5
Dyspnée
Toux
Douleurs thoraciques
Douleurs thoraciques
Maladies sous-jacentes
Enfants
Symptômes respiratoires
Toux
Causes sous-jacentes
Asymptomatique
Hyperinflation
Prévention
5
Prévention
Tabagisme
Polluants environnementaux
Vaccination
Grippe
Pneumocoque
Surveillance
Tests de fonction pulmonaire
Exercices respiratoires
Capacité pulmonaire
Habitudes de vie
Alimentation équilibrée
Traitements
5
Traitement
Bronchodilatateurs
Asthme
Antibiotiques
Infection bactérienne
Corticostéroïdes
Inflammation
Thérapies respiratoires
Bronchodilatateurs
Complications
5
Complications
Pneumothorax
Insuffisance respiratoire
Infections pulmonaires
Hyperinflation
Risques à long terme
Fonction pulmonaire
Facteurs de risque
5
Facteurs de risque
Tabagisme
Polluants
Asthme
BPCO
Maladies pulmonaires
Mode de vie
Sédentarité
Alimentation
Allergies
Problèmes pulmonaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Poumon hyperclair : Questions médicales les plus fréquentes",
"headline": "Poumon hyperclair : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Poumon hyperclair : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-19",
"dateModified": "2025-02-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Poumon hyperclair"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladies pulmonaires",
"url": "https://questionsmedicales.fr/mesh/D008171",
"about": {
"@type": "MedicalCondition",
"name": "Maladies pulmonaires",
"code": {
"@type": "MedicalCode",
"code": "D008171",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C08.381"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Poumon hyperclair",
"alternateName": "Lung, Hyperlucent",
"code": {
"@type": "MedicalCode",
"code": "D019568",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hiromichi Niikawa",
"url": "https://questionsmedicales.fr/author/Hiromichi%20Niikawa",
"affiliation": {
"@type": "Organization",
"name": "Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan."
}
},
{
"@type": "Person",
"name": "Kenneth R McCurry",
"url": "https://questionsmedicales.fr/author/Kenneth%20R%20McCurry",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA."
}
},
{
"@type": "Person",
"name": "Joshua M Diamond",
"url": "https://questionsmedicales.fr/author/Joshua%20M%20Diamond",
"affiliation": {
"@type": "Organization",
"name": "Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."
}
},
{
"@type": "Person",
"name": "Hisashi Oishi",
"url": "https://questionsmedicales.fr/author/Hisashi%20Oishi",
"affiliation": {
"@type": "Organization",
"name": "Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan. hisashi.oishi.c7@tohoku.ac.jp."
}
},
{
"@type": "Person",
"name": "Takashi Hirama",
"url": "https://questionsmedicales.fr/author/Takashi%20Hirama",
"affiliation": {
"@type": "Organization",
"name": "Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid for percutaneous nephrolithotomy.",
"datePublished": "2023-10-26",
"url": "https://questionsmedicales.fr/article/37882229",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD015122.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid: Beyond antifibrinolysis.",
"datePublished": "2022-07-14",
"url": "https://questionsmedicales.fr/article/35834488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/trf.16976"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prehospital Tranexamic Acid for Severe Trauma.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37314244",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1056/NEJMoa2215457"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid in pediatric hemorrhagic trauma.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36044459",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/TA.0000000000003775"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oral tranexamic acid with a triple combination cream versus oral tranexamic acid monotherapy in the treatment of severe melasma.",
"datePublished": "2022-06-07",
"url": "https://questionsmedicales.fr/article/35340120",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jocd.14942"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012140"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies pulmonaires",
"item": "https://questionsmedicales.fr/mesh/D008171"
},
{
"@type": "ListItem",
"position": 4,
"name": "Poumon hyperclair",
"item": "https://questionsmedicales.fr/mesh/D019568"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Poumon hyperclair - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Poumon hyperclair",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Poumon hyperclair",
"description": "Comment diagnostiquer un poumon hyperclair ?\nQuels examens complémentaires sont utiles ?\nQuels signes radiologiques indiquent un poumon hyperclair ?\nLe poumon hyperclair est-il toujours pathologique ?\nQuel rôle joue l'anamnèse dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D019568?mesh_terms=Tranexamic+Acid#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Poumon hyperclair",
"description": "Quels symptômes sont associés au poumon hyperclair ?\nLe poumon hyperclair provoque-t-il des douleurs ?\nY a-t-il des symptômes spécifiques chez les enfants ?\nComment la toux se manifeste-t-elle ?\nLe poumon hyperclair est-il asymptomatique ?",
"url": "https://questionsmedicales.fr/mesh/D019568?mesh_terms=Tranexamic+Acid#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Poumon hyperclair",
"description": "Comment prévenir le poumon hyperclair ?\nY a-t-il des vaccinations recommandées ?\nComment surveiller la santé pulmonaire ?\nLes exercices respiratoires aident-ils ?\nQuelles habitudes de vie adopter ?",
"url": "https://questionsmedicales.fr/mesh/D019568?mesh_terms=Tranexamic+Acid#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Poumon hyperclair",
"description": "Quel traitement pour un poumon hyperclair ?\nLes antibiotiques sont-ils nécessaires ?\nQuand envisager une intervention chirurgicale ?\nLes corticostéroïdes sont-ils efficaces ?\nComment gérer les symptômes respiratoires ?",
"url": "https://questionsmedicales.fr/mesh/D019568?mesh_terms=Tranexamic+Acid#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Poumon hyperclair",
"description": "Quelles complications peuvent survenir ?\nLe poumon hyperclair peut-il entraîner des infections ?\nComment gérer les complications ?\nLe poumon hyperclair est-il réversible ?\nQuels sont les risques à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D019568?mesh_terms=Tranexamic+Acid#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Poumon hyperclair",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes maladies pulmonaires prédisposent-elles ?\nLe mode de vie joue-t-il un rôle ?\nLes allergies sont-elles un facteur ?",
"url": "https://questionsmedicales.fr/mesh/D019568?mesh_terms=Tranexamic+Acid#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un poumon hyperclair ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par radiographie thoracique et éventuellement par scanner."
}
},
{
"@type": "Question",
"name": "Quels examens complémentaires sont utiles ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests fonctionnels respiratoires et une tomodensitométrie peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Quels signes radiologiques indiquent un poumon hyperclair ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de la densité pulmonaire et une augmentation de la transparence sont observées."
}
},
{
"@type": "Question",
"name": "Le poumon hyperclair est-il toujours pathologique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il peut être physiologique chez les jeunes enfants ou en cas d'hyperinflation."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'anamnèse dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'anamnèse aide à identifier des antécédents de maladies respiratoires ou d'exposition."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés au poumon hyperclair ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure une dyspnée, une toux ou des douleurs thoraciques."
}
},
{
"@type": "Question",
"name": "Le poumon hyperclair provoque-t-il des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas directement, mais des douleurs peuvent survenir en raison de maladies sous-jacentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques chez les enfants ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants peuvent présenter des symptômes respiratoires aigus ou chroniques."
}
},
{
"@type": "Question",
"name": "Comment la toux se manifeste-t-elle ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "La toux peut être sèche ou productive, selon la cause sous-jacente du poumon hyperclair."
}
},
{
"@type": "Question",
"name": "Le poumon hyperclair est-il asymptomatique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être asymptomatique, surtout dans les cas d'hyperinflation bénigne."
}
},
{
"@type": "Question",
"name": "Comment prévenir le poumon hyperclair ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et les polluants environnementaux peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations recommandées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vaccination contre la grippe et le pneumocoque est conseillée."
}
},
{
"@type": "Question",
"name": "Comment surveiller la santé pulmonaire ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers et des tests de fonction pulmonaire sont recommandés."
}
},
{
"@type": "Question",
"name": "Les exercices respiratoires aident-ils ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent améliorer la capacité pulmonaire et la santé respiratoire."
}
},
{
"@type": "Question",
"name": "Quelles habitudes de vie adopter ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter une alimentation équilibrée et faire de l'exercice régulièrement est bénéfique."
}
},
{
"@type": "Question",
"name": "Quel traitement pour un poumon hyperclair ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la cause sous-jacente, comme des bronchodilatateurs pour l'asthme."
}
},
{
"@type": "Question",
"name": "Les antibiotiques sont-ils nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne sont nécessaires que si une infection bactérienne est suspectée."
}
},
{
"@type": "Question",
"name": "Quand envisager une intervention chirurgicale ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une chirurgie peut être envisagée en cas de complications graves comme un pneumothorax."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être utilisés pour réduire l'inflammation dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes respiratoires ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des bronchodilatateurs et des thérapies respiratoires peuvent aider à soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme le pneumothorax ou l'insuffisance respiratoire peuvent se produire."
}
},
{
"@type": "Question",
"name": "Le poumon hyperclair peut-il entraîner des infections ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hyperinflation peut prédisposer à des infections pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion dépend de la complication, nécessitant parfois une hospitalisation."
}
},
{
"@type": "Question",
"name": "Le poumon hyperclair est-il réversible ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la cause; certaines conditions peuvent être réversibles avec un traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent une détérioration de la fonction pulmonaire et des complications chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'exposition à des polluants et des antécédents familiaux de maladies respiratoires."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout chez les fumeurs et les personnes exposées."
}
},
{
"@type": "Question",
"name": "Les maladies pulmonaires prédisposent-elles ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme l'asthme ou la BPCO augmentent le risque de poumon hyperclair."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les allergies sont-elles un facteur ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines allergies respiratoires peuvent contribuer à des problèmes pulmonaires, y compris l'hyperclarté."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 13/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan.
Publications dans "Poumon hyperclair" :
3 publications dans cette catégorie
Affiliations :
Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
Department of Transplant Center, Cleveland Clinic, Cleveland, OH, USA.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan. hisashi.oishi.c7@tohoku.ac.jp.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. daink@kuhp.kyoto-u.ac.jp.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
Department of Transplant Center, Cleveland Clinic, Cleveland, OH, USA.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
Department of Cardiothoracic Surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Surgery, University of Florida, Gainesville, Florida, USA.
Publications dans "Poumon hyperclair" :
2 publications dans cette catégorie
Affiliations :
Department of Surgery, University of Florida Health, Gainesville, Florida, USA.
Publications dans "Poumon hyperclair" :
1 publication dans cette catégorie
Affiliations :
Hospital Universitario Puerta del Mar, Cádiz, España. jj_perezguerrero@hotmail.com.
Publications dans "Poumon hyperclair" :
1 publication dans cette catégorie
Affiliations :
Hospital Universitario Puerta del Mar, Cádiz, España.
Publications dans "Poumon hyperclair" :
1 publication dans cette catégorie
Affiliations :
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Texas Health - McGovern Medical School, Houston, TX.
Publications dans "Poumon hyperclair" :
1 publication dans cette catégorie
Affiliations :
Department of Radiology, Division of Thoracic Radiology, NYU Langone Health, New York, NY.
Publications dans "Poumon hyperclair" :
1 publication dans cette catégorie
Affiliations :
Department of Radiology, Division of Thoracic Radiology, NYU Langone Health, New York, NY.
Publications dans "Poumon hyperclair" :
1 publication dans cette catégorie
Affiliations :
Department of Radiology, Lenox Hill Hospital, New York, NY.
Publications dans "Poumon hyperclair" :
Percutaneous nephrolithotomy (PCNL) is the gold standard for the treatment of large kidney stones but comes with an increased risk of bleeding compared to other treatments, such as ureteroscopy and sh...
To assess the effects of TXA in individuals with kidney stones undergoing PCNL....
We performed a comprehensive literature search of the Cochrane Library, PubMed (including MEDLINE), Embase, Scopus, Global Index Medicus, trials registries, other sources of the grey literature, and c...
We included randomized controlled trials (RCTs) that compared treatment with PCNL with administration of TXA to placebo (or no TXA) for patients ≥ 18 years old....
Two review authors independently classified studies and abstracted data. Primary outcomes were: blood transfusion, stone-free rate (SFR), and thromboembolic events (TEEs). Secondary outcomes were: adv...
We analyzed 10 RCTs assessing the effect of systemic TXA in PCNL versus placebo (or no TXA) with 1883 randomized participants. Eight studies were published as full text. One was published in abstract ...
Based on 10 RCTs with substantial methodological limitations that lowered all CoE of effect, we found that systemic TXA in PCNL may reduce blood transfusions, major and minor surgical complications, a...
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthopedic, and gynecological surgical patients. TXA binds plasminogen and preve...
Whether prehospital administration of tranexamic acid increases the likelihood of survival with a favorable functional outcome among patients with major trauma and suspected trauma-induced coagulopath...
We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, ...
A total of 1310 patients were recruited by 15 emergency medical services in Australia, New Zealand, and Germany. Of these patients, 661 were assigned to receive tranexamic acid, and 646 were assigned ...
Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8...
There is strong evidence in adult literature that tranexamic acid (TXA) given within 3 hours from injury is associated with improved outcomes. The evidence for TXA use in injured children is limited t...
Melasma is an acquired pigmentation disorder with a complex multifactorial etiopathogenesis. Oral tranexamic acid (TA) is a promising drug for its treatment and may enhance outcomes when used in combi...
To provide evidence of the efficacy and safety of oral TA as a monotherapy, and in combination with a triple combination cream, for treating melasma in the Hispanic population....
Forty-four female Hispanic patients with melasma were randomly assigned to receive 325 mg of oral TA every 12 h plus f-TCC (fluocinolone-based triple combination cream) every 24 h (group A) or 325 mg ...
There was a 50.04% and 65.45% improvement in mMASI at Weeks 4 and 8, respectively, in group A, compared to baseline, while for Week 16, an improvement of 76.85% was achieved in group B compared to bas...
The combination of oral TA and f-TCC is more effective than oral TA alone in the treatment of severe melasma in Hispanic patients....
In the last decades, tranexamic acid (TXA) has emerged as an essential tool in blood loss management in obstetrics. TXA prophylaxis for postpartum haemorrhage (PPH) has been studied in double-blind, p...
Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood loss and allogeneic red blood cell transfusion in several clinical settings. With a growing emphasis on pa...
Tranexamic acid (TXA) is a common haemorrhage control agent in both emergency department (ED) settings and intra-operatively. While efficacy and potential harms are well-studied, there are no overview...
Tranexamic acid reduces surgical bleeding. Consistent with previous research, the POISE-3 (Peri-Operative Ischemic Evaluation-3) trial found that tranexamic acid reduces major bleeding by 25% and with...
Acne is a chronic, inflammatory skin disorder of pilosebaceous units. Tranexamic acid (TXA) acts as a plasmin inhibitor to reduce blood loss and is also used to treat rosacea due to its anti-inflammat...
The study aimed to evaluate the efficacy of 10% TXA serum in treating acne and its adverse effects....
A randomized, double-blind, placebo-controlled, split-face study was performed on 18 mild-to-moderate acne patients. Patients applied 10% TXA serum on one side of the face and placebo on another side ...
Significant differences in total inflammatory acne counts were observed between TXA and placebo since Week 4 (p = 0.008). TXA mainly reduced papules and pustules, as papule counts significantly decrea...
Topical 10% TXA can reduce inflammatory acne effectively. Adverse effects were minor and treat easily....